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Background: Matrix metalloproteinases (MMPs) are involved in cancer invasion and metastasis. Circulating tumor
cells (CTCs) play role in tumor dissemination and are an independent survival predictor in breast cancer (BC)
patients. The aim of this study was to assess correlation between CTCs and tumor MMP1 in BC.
Methods: Study included 149 primary BC patients treated by surgery from March 2012 to March 2013. Peripheral
blood mononuclear cells (PBMC) were depleted of hematopoietic cells using RossetteSepTM selection kit. RNA
extracted from CD45-depleted PBMC was interrogated for expression of EMT (TWIST1, SNAIL1, SLUG, ZEB1) and
epithelial (CK19) gene transcripts by qRT-PCR. Patient samples with higher epithelial and/or mesenchymal gene
transcripts than those of healthy donors (n = 60) were considered as CTC positive. Expression of MMP1 in surgical
specimens was evaluated by immunohistochemistry.
Results: CTCs were detected in 24.2% patients. CTCs exhibiting only epithelial markers were present in 8.7%
patients, whereas CTCs with epithelial-mesenchymal transition (EMT) markers (CTC_EMT) were observed in 13.4% of
patients and CTCs co-expressing both markers were detected in 2.0% patients. Patients with CTC_EMT in peripheral
blood had significantly increased expression of MMP1 in tumor cells (p = 0.02) and tumor associated stroma (p = 0.05)
than those of patients without CTC_EMT. In multivariate analysis, CTC_EMT and tumor grade were independently
associated with MMP1 expression in cancer cells, while CTC_EMT and Ki67 were independently associated with
MMP1 expression in cancer associated stroma.
Conclusion: Our data suggest link between MMP1 and CTCs with EMT phenotype and support role of MMPs and
EMT in tumor dissemination.
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Circulating tumor cells (CTCs) play an important role in
the metastatic cascade, cancer dissemination and progres-
sion. Prognostic value of CTCs was showed by numerous
trials for metastatic as well as primary breast cancers [1-4].
CTCs constitute a heterogeneous population of cells with
different phenotypes, clinical and biological value [5].
Invasion is one of the first critical steps in the meta-
static cascade that requires changes in cell-to-cell* Correspondence: misomego@gmail.com
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unless otherwise stated.adhesion and cell adhesion to the extracellular matrix
(ECM). Invasion is often accompanied by downregulation
of epithelial molecules on cell surface including E-cadherin,
and upregulation of mesenchymal molecules like N-cadherin,
which is closely associated with mesenchymal cells [6]. In-
vasion is further facilitated by proteolytic degradation of
the ECM, which enables cancer cells to penetrate tissue
boundaries. Degradation of the ECM is predominately
mediated by matrix metalloproteinases (MMPs) and the
urokinase plasminogen activator (uPa) system [7].
Matrix metaloproteinase 1 (MMP1) is a zinc-dependent
endopeptidase with collagen-cleaving activity. MMP1
cleave extracellular matrix components and thus play an
important role in tumor invasion [8]. MMP1 is producedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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MMP1 expression in tumor is associated with tumor evo-
lution, poor prognosis and shortened survival in different
types of tumors including breast cancer [9,10]. Many stud-
ies suggest that overexpression of MMPs is one of the key
events leading to the breast cancer dissemination. Re-
cently, it was shown, that MMPs induce epithelial to
mesenchymal transition and thus increase the invasive
potential of tumor cells [11,12].
In this translational study, we hypothesized, that
MMP1 is involved in CTC release and CTCs are de-
tected more often in breast cancer patients with high
MMP1 expression in primary tumor or tumor associated
stroma. Therefore, we examined expression of MMP1
on breast tumor tissue as well as tumor associated
stroma and correlated them with CTCs in peripheral
blood. We also correlated MMP1 expression with other
patients’ tumor characteristics.Methods
Study patients
As a part of ongoing translational study (Protocol
TRU-SK 002; Chair: M. Mego), treatment naive patients
with stages I–III primary breast cancer (PBC) who were
undergoing definitive surgery were included. From each
patient we obtained peripheral blood for CTCs detec-
tion on the day of surgery and corresponding paraffin-
embedded tumor tissue. Each patient was given a complete
diagnostic evaluation to exclude the presence of distant
metastasis. Patients with concurrent malignancy other
than non-melanoma skin cancer in the previous 5 years
were excluded as well. In all patients, data regarding
age, tumor stage, histology, regional lymph node in-
volvement, hormone receptor status, and HER2 status
were also recorded. All patients agreed to participate in
the study and signed informed consent according to the
IRB-approved protocol.
The study was approved by the Institutional Review
Board (IRB) of the National Cancer Institute of Slovakia
and patients were enrolled between March 2012 and
March 2013. Healthy donors (N = 60) were age-matched
women without breast cancer who were recruited and
consented according to the IRB-approved protocol.
Healthy donors were recruited from staff working in co-
operating institutions except women from departments
directly involved in the study.Detection of CTC in peripheral blood
CTC were detected in peripheral blood by quantitative
real-time polymerase chain reaction (qRT-PCR) based
assay utilizing CD45 positive (CD45+) cells depletion for
CTCs enrichment, as described previously [13].RNA extraction
Peripheral blood was subjected to CD45 depletion using
RossetteSep™ kit (StemCell technologies) according to the
manufacturer’s instructions. CD45-depleted cells were
mixed with TRIzolVR LS Reagent (Invitrogen Corporation,
Carlsbad, CA) and stored at −80°C until it was necessary
to extract RNA according to the manufacturer’s instruc-
tions. All RNA preparation and handling steps took place
in a laminar flow hood, under RNase-free conditions.
RNA concentration was determined by absorbance read-
ings at 260 nm.Identification of gene transcripts in CD45-enriched subsets
Isolated RNA was subjected to quantitative RT-PCR
(qRT-PCR) to detect EMT-inducing transcription factors
(EMT-TF) gene transcripts (TWIST, SNAIL1, SLUG and
ZEB1) and epithelial antigen (CK19). In brief, 2.5 μL of
cDNA were placed in 25 μL of reaction volume containing
12.5 μL of QuantiFast Probe RT-PCR Kit Master Mix,
0.25 μL QuantiFast RT Mix, 8.5 μL water and 1.25 μL of
primers. The following TaqMan assays were purchased
from LifeTechnologies (USA): Twist1: Hs00361186_m1;
Snail1: Hs00195591_m1; Slug: Hs00161904_m1; Zeb1:
Hs01566408_m1; Gapdh Hs99999905_m1; Ck19 Hs007
61767_s1. Amplicons or probes spanned intron–exon
boundaries, with the exception of CK19. Amplification
was performed on an Eppendorf Realplex Real-Time PCR
system (Eppendorf, Germany) using the cycling program:
95°C for 10 min; 40 cycles of 95°C for 15 sec and 60°C for
60 sec. All samples were analyzed in triplicate. Calibrator
samples were run with every plate to ensure consistency
of the PCR. For all fluorescence-based RT-PCR, fluores-
cence was detected between 0 and 40 cycles for the con-
trol and marker genes in single-plex reactions, which
allowed for the deduction of the cycles at threshold (Ct)
value for each product. Expression of the genes of interest
was calibrated against expression of the housekeeping
gene, GAPDH. Target cDNA was quantified using the
delta-Ct method with the formula: 1 = 2 Ct(target-
GAPDH).CTC definition
Patient samples with higher Ck19 gene transcripts than
those of healthy donors were considered as epithelial
CTCs positive (CTC_EP), while patient samples with
higher EMT-TF (Twist1, Snail1, Slug and Zeb1) gene
transcripts than those of healthy donors were considered
as CTC_EMT positive.
The highest expression levels of the CK19 and EMT-
inducing TF gene transcripts relative to that of Gapdh
were 3.4 × 10 −3, 2.0 × 10−4, 1 × 10−2 and 2.2 × 10−2 for
Ck19, Twist1, Snail1 and Zeb1, while Slug transcripts were
not detected in any of the samples from healthy donor.
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positivity.
Tumor pathology
Pathology review was conducted at the Department of
Pathology, Faculty of Medicine, Comenius University, by
pathologists (ZC, LD and PJ) associated with the study.
Diagnosis and tumor samples
The study included tumor specimens from 149 patients.
All specimens were classified according to the WHO
Classification of 2004. The block containing the most
representative part of the haematoxylin and eosin (H&E)
stained tumor was identified by microscopy and subse-
quently used for IHC analysis.
Tissue microarray construction
According to tumor histology, one or two representative
tumor areas were identified on H&E stained sections.
Sections were matched to their corresponding wax blocks
(the donor blocks), and 3-mm diameter cores of the
tumor were removed from donor blocks with the multi-
purpose sampling tool Harris Uni-Core (Sigma-Aldrich,
Steinheim, Germany) and inserted into the recipient mas-
ter block. The recipient block was cut into 5-μm sections,
and the sections were transferred to coated slides.
Immunohistochemical (IHC) staining
Slides were deparaffinised and rehydrated in phosphate
buffered saline solution (10 mM, pH 7.2). The tissue epi-
topes were demasked using the automated water bath
heating process in Dako PT Link (Dako, Glostrup,
Denmark); the slides were incubated in pH 6.0 citrate re-
trieval buffer at 98°C for 20 minutes. The slides were sub-
sequently incubated overnight at room temperature with
the primary rabbit polyclonal antibody against MMP1
(LSBio, MMP-1, LS-B1229) diluted 1:40 in Dako REAL
antibody diluent (Dako, Glostrup, Denmark) and immuno-
stained using anti-mouse/anti-rabbit immuno-peroxidase
polymer (EnVision FLEX/HRP, Dako, Glostrup, Denmark)
for 30 minutes at room temperature, according to the
manufacturer’s instructions. For visualisation, the slides
were reacted with diaminobenzidine substrate-chromogen
solution (DAB, Dako, Glostrup, Denmark) for 5 minutes.
Finally, the slides were counterstained with haematoxylin.
As negative control, breast tissue was subjected to the
same staining procedure without reaction with the primary
antibody.
Immunohistochemical stain scoring
Tumor cores were independently assessed by pathologists
(ZC, LD and PJ) who were blinded to clinico-pathological
data. In cases of disagreement, the result was reached
by consensus. The result of the immunohistochemicalanalyses was expressed by a weighted histoscore, evalu-
ating both the percentage of positive cells (PP) and the
staining intensity (SI) of the nuclei or cytoplasm.
Briefly, the proportion of cells with nuclear staining
was multiplied by the intensity of staining to provide a
histoscore ranging from 0–300. The histoscore was
calculated as follows: Score = (0 × percentage not
stained) + (1 × percentage weakly stained) + (2 × per-
centage moderately stained) + (3 × percentage strongly
stained) [14].
Statistical analysis
Patient characteristics were tabulated. The patients’ char-
acteristics were summarized using the median (range)
for continuous variables and frequency (percentage) for
categorical variables. Normality of distribution was tested
by the Kolmogorov-Smirnoff test. If normally distributed,
sample means were tested by Student t-test or analysis of
variance (ANOVA) with Bonferroni’s or Tamhane’s cor-
rections, depending on homogeneity of variance. Non-
parametric Mann–Whitney U or Kruskal-Wallis H test
were used for non-normally distributed data. A multivari-
ate linear regression model was built using a step-wise re-
gression technique, regression coefficients remained in the
model at significance level of 0,05. MMP1 expression
levels were analyzed as continuous variables. Because the
MMP expression levels were highly skewed, Box-Cox
transformations [15] were used for the determination of
p-values, with optimum λ = 0,19 for MMP1 in tumor
stroma and optimum λ = 0,16 for MMP1 expression in
tumor cells. All p values presented are two-sided, and
associations were considered significant if the p value is
less or equal to 0.05. Statistical analyses were performed
using NCSS 2007 software (Hintze J, 2007, Kaysville,
Utah, USA).
Results
The study population consisted of 149 primary breast
cancer patients with median age of 60 years (range: 31–
83 years). Patients’ characteristics are shown in Table 1.
The majority of patients had hormone receptor positive
(87.2%), node negative (61.1%) tumors; 22 (14.8%) pa-
tients had HER-2/neu amplified tumors.
CTC detection
To determine overexpression of the EMT-TF gene tran-
scripts and Ck19 in PBC patients, we compared the ex-
pression levels in patient samples with those of HDs.
Relative to the highest levels of Snail and Zeb1 tran-
scripts detected in HD samples, none of the patient sam-
ples overexpressed these gene transcripts. Among the
patient samples, Twist1, Slug, and Ck19 transcripts were
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samples, respectively. Totally, CTCs were detected in 36
(24.2%) of patients. CTCs with only epithelial markers
were present in peripheral blood of 13 (8.7%) patients;
CTCs with EMT phenotype were present in 20 (13.4%)
of patients, while in 3 (2.0%) of patients CTCs exhibited
both epithelial and mesenchymal markers. In one patient
sample, there was overlap in overexpression of EMT-TF
gene transcripts (Slug and Twist1).Correlation between MMP1 expression and CTC and
patients’/tumor characteristics
MMP1 expression at least 1+ and higher was detected in
104 (69.8%) of samples in breast tumor cells and in 120
(80.5%) samples of tumor associated stroma (p = 0.04)
(Figure 1). Mean ± SEM (standard error of mean) for
MMP1 expression histoscore in tumor associated stroma
was significantly higher compared to breast tumor cells
(32.8 ± 3.4 vs. 49.1 ± 5.1, p = 0.05). Expression of MMP1
in relation to CTCs and various clinicopathological char-
acteristics is shown in Table 2.
We observed an association between CTC_EMT and
expression of MMP1 in breast cancer cells as well as in
cancer associated stroma (Table 2), and found no correl-
ation between CTC_EP and MMP1 expression. MMP1
expression in breast cancer cells was associated with high
tumor grade, and increased proliferation (high Ki67),
while MMP1 expression in tumor associated stroma, be-
sides high tumor grade and increased proliferation, corre-
lated with invasive ductal histology (Table 2). There was
no association between expression of MMP1 and ER/PR
status, HER2/neu amplification or axillary lymph node
status (Table 2).
In multivariate analysis CTC_EMT (p = 0.03) and tumor
grade (p = 0.01) were independently associated with MMP1
expression in breast tumor cells, while Ki-67 (p = 0.0001)
and CTC_EMT (p = 0.04) were independently associated
with MMP1 expression in tumor associated stroma
(Tables 3 and 4).
Discussion
In this translational study, we showed association be-
tween CTC with EMT phenotype (CTC_EMT) and
MMP1 expression in primary breast cancer. This associ-
ation was observed for MMP1 expression in cancer cells
as well as in cancer associated stroma. MMP1 expres-
sion was increased in primary tumors with poor prog-
nostic features such as high grade tumors with increased
proliferation (Ki 67 > 20%) which is consistent with pre-
vious observations [9]. We also found association be-
tween ductal carcinoma histology and MMP1 expression
as described previously [16]; however, in our study, this
association was statistically significant only for tumor as-
sociated stroma.
Breast cancer represents highly complex tissue com-
posed of cancer cells and stromal cell compartments con-
taining different types of mesenchymal cells. MMPs, in
breast cancer, are produced by cancer cells as well as can-
cer associated stroma and are involved in cancer progres-
sion through multiple mechanisms. Degradation of ECM
by MMPs facilitates movement of cancer cells through
ECM. MMPs also disrupt cell-cell and cell-ECM adhe-
sions that result in the release of individual tumor cells
from epithelial sheets, and initiating signaling pathways
Figure 1 MMP1 expression in primary breast tumors. Immunohistochemical reaction with anti-MMP1 monoclonal antibody. Original
magnification × 400 visualisation with 3,3′-diaminobenzidine. a) staining intensity 0, b) staining intensity 1+, c) staining intensity 2+, d) staining
intensity 3 + .
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terns that are responsible for increased migration and in-
vasion of breast cancer cells [7,11,17]. MMPs could also
impact cancer cell behaviour due to their ability to cleave
growths factors, cell surface receptors, cell adhesion mole-
cules and chemokines [7,16]. Therefore, MMPs are prom-
ising therapeutic targets in breast cancer and several trials
evaluating drugs that interfere with MMPs function are
ongoing [reviewed by 11].
EMT is believed to play an important role in intravasa-
tion and the release of CTCs, and the expression of
EMT-inducing TF gene transcripts in breast cancer has
been associated with poor prognosis [18]. EMT has been
previously linked with cancer stem cell properties [19]
which have been associated with increased therapeutic
resistance [20-22]. MMPs have been associated with
EMT in cancer progression by several mechanisms [11].
Elevated levels of MMPs in the tumor microenviroment
can directly induce EMT in epithelial cells. Cancer cells
that undergo EMT could produce more MMPs further
supporting cell invasion and metastasis and finally, EMT
can generate activated stromal like cells that drive can-
cer progression via further MMPs production [11]. The
most important of these is MMPs mediated activation of
EMT that was seen in variety of epithelial tumors and
has been best characterized in mammary epithelial cells
[11]. Our observation thus further support association
between MMPs and EMT in breast cancer.
EMT of tumor cells could produce stromal-like cells
that could further facilitate tumor progression through
the production of MMPs. Myofibroblasts are key com-
ponents of cancer associated stroma in breast cancerand these cells have important tumor promoting activity.
Myofibroblasts can be derived through activation of
stromal fibroblast or circulating fibrocytes; however, re-
cent studies in mouse models have shown, that myofi-
broblasts can be derived from epithelial cells by EMT, as
well [23-26]. In our study, we observed an association
between CTC_EMT and MMP1 expression in both can-
cer cells as well as in cancer associated stroma. Expres-
sion of MMP1 in the stromal compartment of breast
carcinomas possibly represents two populations of cells:
EMT transformed neoplastic cells and stromal fibroblas-
tic cells that undergo activation of EMT induced TFs
due to growth factors produced by the tumor [27]. How-
ever, we don’t know exactly, if an observed association
between CTC_EMT and MMP1 in tumor stroma, was
due to expression of MMP1 in stromal fibroblasts, or
stromal like cancer cells that underwent EMT.
The flow of cancer cells may not be unidirectional.
Experimental data suggest, that CTCs can be released
from metastatic tumors and then rejoin the tumor of
origin, a process termed ‘self seeding’ [28,29]. It seems,
that self-seeding is a major driver of tumor progression
in solid tumors and that CTCs are mediators of tumor
self-seeding [28]. CTCs are an independent prognostic
factor in breast cancer and probably represent surro-
gate marker for tumor self-seeding ability. In seminal
work, Kim et al. observed that MMP1 is a mediator of
CTCs infiltration into mammary tumors [28] and are
involved in tumor self-seeding in an animal model.
Our translational data are consistent with these obser-
vations and further support role of MMP1 in tumor
self-seeding.
Table 2 MMP1 expression in tumor cells and tumor stroma
Variable MMP1 expression histoscore in tumor cells MMP1 expression histoscore in tumor associated stroma
N Mean SEM Median P-value Mean SEM Median P-value
All 149 32.8 3.4 15 NA 49.1 5.1 20 NA
T-stage
1 105 30.6 4.0 14 0.28 49.7 6.1 20 0.76
> 1 44 44.0 38.2 17 43.0 47.6 20
N-stage
0 91 32.1 4.4 14 1.00 44.7 6.5 20 0.29
> 1 58 34.0 5.5 18 55.9 8.1 20
Grade
1 and 2 95 27.0 4.2 10 0.007 37.9 6.2 6 0.0006
3 54 43.2 5.6 30 69.2 8.3 50
Histology
IDC 128 34.3 3.7 20 0.15 53.8 5.4 20 0.0022
Other 21 23.6 9.0 4 20.8 13.3 1
Hormone receptor status
Negative 19 42.0 9.5 20 0.26 70.7 14.5 50 0.18
Positive 130 31.5 3.6 13 46.1 5.4 20
HER2 status
Negative 127 30.4 3.7 10 0.18 45.0 5.5 20 0.29
Amplified 22 47.1 8.8 25 72.5 13.1 40
Ki 67 (cut-off 20%)
Low 92 28.6 4.3 10 0.04 34.7 6.2 10 0.0006
High 56 39.7 5.5 25 72.8 7.9 50
Lymphovascular invasion
Present 35 41.0 7.0 20 0.10 48.2 10.5 20 0.83
Absent 114 30.3 3.9 11 49.4 5.8 20
Baseline CTC
CTC Epithelial
Negative 133 32.9 3.6 16 0.35 48.6 5.4 20 0.50
Positive 16 32.1 10.4 3 53.0 15.5 11
CTC EMT
Negative 126 30.2 3.7 10 0.02 45.7 5.5 20 0.05
Positive 23 47.0 8.6 40 68.5 13.1 50
CTC Any
Negative 113 31.3 3.9 10 0.47 47.9 5.8 20 0.75
Positive 36 37.5 6.9 20 53.0 10.5 20
Table 3 Multivariate logistic regression model for
expression of MMP1 in tumor cells
Parameter T Statistic P-value
Tumor grade (1 and 2 vs. 3) 2.59 0.0106
CTC_EMT present vs. absent 2.22 0.0277
Table 4 Multivariate logistic regression model for
expression of MMP1 in tumor associated stroma
Parameter T Statistic P-value
Ki 67 (high vs. low) 3.94 0.0001
CTC_EMT present vs. absent 2.03 0.0444
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can also be reversible. Therefore, it usually produces
cells with a spectrum of intermediate phenotypic states.
Cells can advance to differing extents through an EMT
program, progressively acquiring mesenchymal features
as they shed epithelial ones [5]. Cells that have entered
an EMT program rarely shed all of their pre-existing epi-
thelial features. In the context of carcinoma pathogenesis,
neoplastic cells may reside in a state in which they coex-
press newly acquired mesenchymal markers together with
retained epithelial ones [13,30,31]. For these reasons our
distinction of two CTCs subpopulation (CTC-EP, CTC-
EMT) may represent some study limitations.
Conclusion
In conclusion, in this prospective translational study, we
for the first time showed association between CTC_EMT
and expression MMP1 in primary tumor tissue. We sup-
pose that the therapeutical targeting of MMP1 could lead
to decreased MMP1-induced EMT and subsequently, to
decrease of CTC_EMT, with implications for tumor dis-
semination and treatment resistance. Future studies will
be needed to identify expression of other proteins in
tumor tissue associated with presence of CTCs in the per-
ipheral blood. These proteins could represent surrogate
markers for biologically more aggressive disease and could
represent potentially new therapeutic targets to inhibit
metastatic process.
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